Search - tctmd.com

Displaying 221 - 240 of 378

Sort: Relevancy | Date

High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk

News Daily News

High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk

Michael O'Riordan

July 01, 2019

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

News Daily News

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

June 26, 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

Higher Risk of Intracranial Hemorrhage With Aspirin in Primary Prevention

News Daily News

Higher Risk of Intracranial Hemorrhage With Aspirin in Primary Prevention

Michael O'Riordan

May 20, 2019

Even in the DOAC Era, Women Less Likely Than Men to Receive Anticoagulation for A-fib

News Conference News HRS 2019

Even in the DOAC Era, Women Less Likely Than Men to Receive Anticoagulation for A-fib

May 17, 2019

Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure

News Daily News

Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure

Michael O'Riordan

May 06, 2019

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

News Conference News ACC 2019

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

Yael L. Maxwell

March 27, 2019

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

News Conference News ACC 2019

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Yael L. Maxwell

March 22, 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

News Daily News

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Michael O'Riordan

March 01, 2019

DOACs Maintain Advantage Over Warfarin in A-fib Patients With Low Body Weight

News Daily News

DOACs Maintain Advantage Over Warfarin in A-fib Patients With Low Body Weight

February 25, 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

News Conference News ISC 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

February 13, 2019

Cilostazol-Based DAPT Safe, Effective in Patients at High Risk for Recurrent Stroke

News Conference News ISC 2019

Cilostazol-Based DAPT Safe, Effective in Patients at High Risk for Recurrent Stroke

February 12, 2019

Age Shouldn’t Be a Barrier to Statin Therapy, Meta-analysis Suggests

News Daily News

Age Shouldn’t Be a Barrier to Statin Therapy, Meta-analysis Suggests

Michael O'Riordan

February 08, 2019

Most Cardiovascular Drugs Can Be Safely Used in Pregnancy, Review Suggests

News Daily News

Most Cardiovascular Drugs Can Be Safely Used in Pregnancy, Review Suggests

February 01, 2019

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

News Daily News

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

January 08, 2019

Top News in Heart Failure: 2018

News Features

Top News in Heart Failure: 2018

December 28, 2018

FDA Warns of Stroke and Arterial Dissection Risk With MS Drug

News Daily News

FDA Warns of Stroke and Arterial Dissection Risk With MS Drug

November 29, 2018

Angina Without Obstructive Stenosis: No Longer a ‘Black Box’ Mystery, Say Experts

News Daily News

Angina Without Obstructive Stenosis: No Longer a ‘Black Box’ Mystery, Say Experts

Michael O'Riordan

November 23, 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.